Search results for " Recurrence"

showing 10 items of 534 documents

Clinical and Molecular-Based Approach in the Evaluation of Hepatocellular Carcinoma Recurrence after Radical Liver Resection

2021

Background: Hepatic resection remains the treatment of choice for patients with early-stage HCC with preserved liver function. Unfortunately, however, the majority of patients develop tumor recurrence. While several clinical factors were found to be associated with tumor recurrence, HCC pathogenesis is a complex process of accumulation of somatic genomic alterations, which leads to a huge molecular heterogeneity that has not been completely understood. The aim of this study is to complement potentially predictive clinical and pathological factors with next-generation sequencing genomic profiling and loss of heterozygosity analysis. Methods: 124 HCC patients, who underwent a primary hepatic …

Cancer Researchmedicine.medical_specialtyHepatitis C virusSubgroup analysisLower riskmedicine.disease_causelcsh:RC254-282GastroenterologyArticlePathogenesisLoss of heterozygositynext-generation sequencing.03 medical and health sciences0302 clinical medicineInternal medicineMedicinePTENHCCHCC recurrencebiologybusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncology030220 oncology & carcinogenesisHepatocellular carcinomaliver resectionbiology.proteinnext-generation sequencingloss of heterozygosity030211 gastroenterology & hepatologyLiver functionbusinessCancers
researchProduct

Health status of young children with cancer following discontinuation of therapy.

1987

This paper reports late effects and health status of 198 children who had cancer or leukemia diagnosed under 2 years of age and their therapies electively withdrawn. This series (92 neuroblastoma (NBL), 57 Wilms' tumor (WT), 46 acute lymphoblastic leukemia (ALL), and 3 non-Hodgkin's lymphoma) was followed for 1-12 years after discontinuation of therapy. Thirty-three children were diagnosed before 1973, 92 between 1973 and 1977, and 73 after 1977 in 16 Italian Pediatric Oncology Centers. As of December 1983, 176 children were reported to be alive and without evidence of primary cancer by physicians responsible for their care. One child died from a second primary tumor, two from late recurren…

Cancer Researchmedicine.medical_specialtyPediatricsmedicine.medical_treatmentAntineoplastic AgentsGrowthNeoplasms Multiple PrimaryLeukoencephalopathyMuscular DiseasesNeoplasmsAcute lymphocytic leukemiamedicineHumansKyphoscoliosisChemotherapyRadiotherapybusiness.industryInfantCancerSequelamedicine.diseaseLeukemia LymphoidDiscontinuationSurgeryRadiation therapyOncologyChild PreschoolPediatrics Perinatology and Child HealthBone DiseasesNeoplasm Recurrence LocalNervous System DiseasesbusinessFollow-Up Studies
researchProduct

Impact of sentinel node biopsy on long-term quality of life in breast cancer patients

2013

Background: The aim of this study was to assess long-term quality of life (QoL) over a period of 6 years in women with breast cancer (BC) who underwent sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or SLNB followed by ALND. Methods: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ)-C30 and the EORTC-QLQ-BR-23 questionnaires were used to assess QoL before surgery, just after surgery, 6, 12 and 72 months later. The longitudinal effect of surgical modalities on QoL was assessed with a mixed model analysis of variance for repeated measurements. Results: Five hundred and eighteen BC patients were initially include…

Cancer Researchmedicine.medical_specialtyTime FactorsHealth StatusBreast surgerymedicine.medical_treatmentSentinel lymph nodeBreast Neoplasmsbreast cancerBreast cancerQuality of lifeSurveys and QuestionnairesBody ImageHumansMedicineAgedSentinel Lymph Node Biopsybusiness.industryCarcinoma Ductal BreastAxillary Lymph Node DissectionCancerMiddle AgedSentinel nodemedicine.diseasehumanitiesSurgeryLymphedemaquality of lifeOncologyClinical StudyLymph Node ExcisionFemaleNeoplasm Recurrence LocalbusinessFollow-Up StudiesBritish Journal of Cancer
researchProduct

Intravesical mitoxantrone in superficial bladder tumours (Ta-T1)

1993

Abstract 36 patients with histologically proven grade G1–G2, Ta-T1 transitional cell carcinoma of the bladder were introduced, after transurethral resection (TUR), into a study of intravesical chemoprophylaxis with mitoxantrone (20 mg diluted in 50 ml). After a mean follow-up of 23 months, 16 (50%) patients showed a superficial recurrence with a mean recurrence rate of 0.56 per year. In 19 patients with recurring tumours the mean recurrence rate decreased from 1.65 to 0.58 per year. 9 patients (25.7%) suffered from a chemical cystitis that in 2 cases (5.7%) required treatment interruption.

Cancer Researchmedicine.medical_specialtymedicine.medical_treatmentUrologyResectionCystitismedicineHumansCarcinoma Transitional CellMitoxantroneChemotherapyUrinary bladderbusiness.industrymedicine.diseaseSurgeryChemical cystitisAdministration IntravesicalTransitional cell carcinomamedicine.anatomical_structureUrinary Bladder NeoplasmsOncologyTreatment interruptionChemoprophylaxisMitoxantroneNeoplasm Recurrence Localbusinessmedicine.drugEuropean Journal of Cancer
researchProduct

Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after live…

2022

BackgroundThough the precise criteria for accessing LT are consistently being applied, HCC recurrence (HCC-R_LT) still affects more than 15% of the patients. We analyzed the clinical, histopathological, and biological features of patients with HCC to identify the predictive factors associated with cancer recurrence and survival after LT.MethodsWe retrospectively analyzed 441 patients with HCC who underwent LT in our center. Overall, 70 (15.8%) of them developed HCC-R_LT. We matched them by age at transplant and etiology with 70 non-recurrent patients. A comparable cohort from the Liver Transplant Centre of Bologna served as validation. The clinical and biochemical characteristics and pre-LT…

Cancer ResearchneoangiogenesisimmunocytochemistryrecurrenceOncologyliver transplantationneoangiogenesiangiopoietin-2hepatocellular carcinomaangiopoietin-2; hepatocellular carcinoma; immunocytochemistry; liver transplantation; neoangiogenesis; recurrence; survivalsurvival
researchProduct

Male breast cancer.

2010

Male breast cancer (MaleBC) is a rare disease, accounting for <1% of all male tumors. During the last few years, there has been an increase in the incidence of this disease, along with the increase in female breast cancer (FBC). Little is known about the etiology of MaleBC: hormonal, environmental and genetic factors have been reported to be involved in its pathogenesis. Major risk factors include clinical disorders carrying hormonal imbalances, radiation exposure and, in particular, a positive family history (FH) for BC, the latter suggestive of genetic susceptibility. Rare mutations in high-penetrance genes (BRCA1 and BRCA2) confer a high risk of BC development; low-penetrance gene mutati…

CounselingMalemedicine.medical_specialtymedicine.medical_treatmentchemotherapyHyperestrogenismsurvivalBreast Neoplasms MalesurgeryBreast cancerRisk Factorspolycyclic compoundsmedicineHumansgeneticsFamily historyskin and connective tissue diseaseshormonal treatmentneoplasmsradiotherapyGynecologytherapybusiness.industryCarcinomaCancerHematologybacterial infections and mycosesmedicine.diseasePrognosisMale breast cancergenetics; hormonal treatment; male breast cancer; survival; local recurrence; radiotherapy; therapy; surgery; chemotherapyRadiation therapyOncologyMale breast cancerbacteriaFemaleBreast diseaselocal recurrencemedicine.symptombusinessAlgorithmsRare disease
researchProduct

Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials

2019

Abstract The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing datasets of primary tumor samples mainly from early stage colon cancer patients. Consequently, rectal tumors and stage IV tumors (possibly reflective of more aggressive disease) were underrepresented, and no chemo- and/or radiotherapy pretreated samples or metastatic lesions were included. In view of their possible effect on gene expression and consequently subtype classification, sample source and treatments received by the patients before collection must be ca…

Data Analysis0301 basic medicineOncologymedicine.medical_specialtyMicroarrayconsensus molecular subtypesColorectal cancermedicine.medical_treatmentDatasets as TopicReviews03 medical and health sciencesstratification0302 clinical medicineBiasCàncer colorectalInternal medicineBiomarkers TumormedicineHumansRNA-SeqOligonucleotide Array Sequence AnalysisClinical Trials as Topicclinical trialsbusiness.industryPatient SelectionBiochemical markersbiomarkersChemoradiotherapypersonalized medicineHematologyPrognosismedicine.diseaseChemotherapy regimenPrimary tumorColorectal cancerSubtypingRadiation therapyClinical trialTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisMutationgene expressionPersonalized medicineNeoplasm Recurrence LocalColorectal NeoplasmsbusinessMarcadors biomquímics
researchProduct

Use of the KSVM-based system for the definition, validation and identification of the incisional hernia recurrence risk factors

2019

BACKGROUND: Incisional hernia is one of the most common complications after abdominal surgery with an incidence rate of 11 to 20% post laparotomy. Many different factors can be considered as risk factors of incisional hernia recurrence. The aim of this study is to confirm and to validate the incisional hernia recurrence risk factors and to identify and to validate new ones. METHODS: In the period from July 2007 to July 2017, 154 patients were selected and subjected to incisional hernia repair. The surgical operations were conducted under general anaesthesia. Patients received antibiotic prophylaxis when indicated, according to the hospital prophylaxis scheme. Inclusion criteria of the study…

Data AnalysisMaleAge FactorsDatasets as TopicIncisional hernia - Risk factors - Recurrence - KSVM.ComorbidityAnesthesia GeneralAntibiotic ProphylaxisMiddle AgedSensitivity and SpecificityBody Mass IndexMachine LearningSex Factorssurgical procedures operativeRecurrenceRisk Factorsincisional hernia risk factorsData MiningHumansIncisional HerniaFemale
researchProduct

Real-World Data Analysis of Pregnancy-Associated Breast Cancer at a Tertiary-Level Hospital in Romania

2020

Background and objectives: Breast cancer is among the most common cancer types encountered during pregnancy. Here, we aimed to describe the characteristics, management, and outcomes of women with pregnancy-associated breast cancer at a tertiary-level hospital in Romania. Material and Methods: We retrospectively and prospectively collected demographic, oncological, and obstetrical data for women diagnosed with cancer during pregnancy, and who elected to continue their pregnancy, between June 2012 and June 2020. Complete data were obtained regarding family and personal medical history and risks factors, cancer diagnosis and staging, clinical and pathological features (including histology and …

Data AnalysisPediatricsmedicine.medical_specialtymedicine.medical_treatmentbreast cancer; pregnancy-associated breast cancer; RomaniaBreast NeoplasmsArticleBreast cancerbreast cancerPregnancyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChildbirthMedical historyStage (cooking)ChildNeoplasm StagingRetrospective Studieslcsh:R5-920PregnancyChemotherapybusiness.industrypregnancy-associated breast cancerRomaniaCancerGeneral Medicinemedicine.diseaseHospitalsNeoadjuvant TherapyRadiation therapyFemaleNeoplasm Recurrence Locallcsh:Medicine (General)businessMedicina
researchProduct

Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

2021

Item does not contain fulltext Introduction and objectives: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis in order to adequately stage the patient. It is well known that the presence of detrusor muscle in the specimen is a prerequisite to minimize the risk of under staging. Persistent disease after resection of bladder tumors is not uncommon and is the reason why the European Guidelines recommended a re-TUR for all T1 tumors. It was recently published that when there is muscle in the specimen, re-TUR does not influence progression or cancer specific survival. We present here the patient and tumor factors th…

Detrusor musclemedicine.medical_specialty030232 urology & nephrologyUrologyDiseaseLogistic regression03 medical and health sciencesTumor Status0302 clinical medicineRe-transurethral resection of the bladderRecurrenceRisk FactorsUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]MedicineHumansStage (cooking)Non-muscle invasive bladder cancer; Re-transurethral resection of the bladder; Residual disease; Recurrence; ProgressionNeoplasm StagingRetrospective StudiesUnivariate analysisCarcinoma Transitional CellProgressionbusiness.industryRetrospective cohort studyGeneral MedicineResidual diseaseReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Settore MED/24medicine.anatomical_structureUrinary Bladder NeoplasmsConcomitantNon-muscle invasive bladder cancerbusiness
researchProduct